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Abstract
Background: Shoulder disorders are a common health problem in western societies. Several treatment protocols have
been developed for the clinical management of persons with shoulder pain. However available evidence does not support
any protocol as being superior over others. Systematic reviews provide some evidence that certain physical therapy
interventions (i.e. supervised exercises and mobilisation) are effective in particular shoulder disorders (i.e. rotator cuff
disorders, mixed shoulder disorders and adhesive capsulitis), but there is an ongoing need for high quality trials of physical
therapy interventions. Usually, physical therapy consists of active exercises intended to strengthen the shoulder muscles
as stabilizers of the glenohumeral joint or perform mobilisations to improve restricted mobility of the glenohumeral or
adjacent joints (shoulder girdle). It is generally accepted that a-traumatic shoulder p r o b l e m s  a r e  t h e  r e s u l t  o f
impingement of the subacromial structures, such as the bursa or rotator cuff tendons. Myofascial trigger points (MTrPs)
in shoulder muscles may also lead to a complex of symptoms that are often seen in patients diagnosed with subacromial
impingement or rotator cuff tendinopathy. Little is known about the treatment of MTrPs in patients with shoulder
disorders.
The primary aim of this study is to investigate whether physical therapy modalities to inactivate MTrPs can reduce
symptoms and improve shoulder function in daily activities in a population of chronic a-traumatic shoulder patients when
compared to a wait-and-see strategy. In addition we investigate the recurrence rate during a one-year-follow-up period.
Methods/Design:  This paper presents the design for a randomized controlled trial to be conducted between
September 2007 – September 2008, evaluating the effectiveness of a physical therapy treatment for non-traumatic
shoulder complaints. One hundred subjects are included in this study. All subjects have unilateral shoulder pain for at
least six months and are referred to a physical therapy practice specialized in musculoskeletal disorders of the neck-,
shoulder-, and arm.
After the initial assessment patients are randomly assigned to either an intervention group or a control-group (wait and
see). The primary outcome measure is the overall score of the Dutch language version of the DASH (Disabilities of Arm,
Shoulder and Hand) questionnaire.
Discussion: Since there is only little evidence for the efficacy of physical therapy interventions in certain shoulder
disorders, there is a need for further research. We found only a few studies examining the efficacy of MTrP therapy for
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shoulder disorders. Therefore we will perform a randomised clinical trial of the effect of physical therapy interventions
aimed to inactivate MTrPs, on pain and impairment in shoulder function in a population of chronic a-traumatic shoulder
patients. We opted for an intervention strategy that best reflects daily practice. Manual high velocity thrust techniques
and dry-needling are excluded. Because in most physical therapy interventions, blinding of the patient and the therapist
is not possible, we will perform a randomised, controlled and observer-blinded study.
Trial Registration: This randomized clinical trial is registered at current controlled trials ISRCTN75722066.
Background
Shoulder pain is a common health problem in western
societies. There are substantial differences in reported
prevalence in the general population. The one-year preva-
lence of shoulder disorders has been reported to range
from 20% to 50%. This wide range is strongly influenced
for example by the definition of shoulder disorders,
including or excluding limited motion, age, gender and
anatomic area [1-3]. Of all shoulder patients who attend
primary care physicians 50% recover within 6 months,
meaning they do not seek any medical help after the first
episode[1,4-6]. Chronicity and recurrence of symptoms
are common [7,8]. According to the guidelines of the
Dutch College of General Practioners [9], the recom-
mended management of shoulder symptoms starts with
educational information about the natural course of
shoulder pain combined with the advise to avoid irritat-
ing and loading activities. The use of analgesics or NSAIDs
is recommended for the first two weeks. When no recov-
ery occurs within two weeks, subacromial or intra-articu-
lar injection therapy with corticosteroids are administered
and eventually repeated. Finally, physical therapy is only
recommended after a 6-week period when there are func-
tional limitations (specifically an activating and time-con-
tingent approach). International guidelines for shoulder
pain, including the Clinical Guideline of Shoulder pain of
the American Academy of Orthopaedic Surgeons [10] and
the Shoulder Guideline of the New Zealand Guidelines
Group[11] differ more or less from the Dutch guidelines
in classification, recommended interventions and time-
line, and order of interventions. Scientific evidence from
randomized clinical trials, meta-analyses or systematic
reviews for either the efficacy of multimodal rehabilita-
tion, injection therapy, medication, surgery or physical
therapy or the order of application of commonly used
therapies is lacking [12-16].
An alternative approach to the management of persons
with shoulder problems consists of a treatment aimed at
inactivating MTrPs and eliminating factors that perpetuate
them. MTrPs may be inactivated by manual techniques
(such as compression on the trigger point or other mas-
sage techniques), cooling the skin with ethyl chloride
spray or with ice-cubes followed by stretching of the
involved muscle, trigger point needling using an acupunc-
ture needle, or injection with local anaesthetics or Botuli-
num toxin, followed by ergonomic advises, active
exercises, postural correction, and relaxation (with or
without biofeedback)[17,18]. Over the years, MTrPs are
increasingly accepted in the medical literature. Clinical,
histological, biochemical and electrophysiological
research has provided biological plausibility for the exist-
ence of MTrPs [19-24].
MTrPs are defined as exquisitely tender spots in discrete
taut bands of hardened muscle that produce symptoms
[25,26]. A previous study showed that MTrPs can be
detected reliably by trained physiotherapists [27]. Palpa-
tion is still the only reliable method to diagnose myofas-
cial pain clinically. In reviews addressing the efficacy of
interventions in shoulder patients, MTrP therapy and
myofascial pain are rarely mentioned [15]. However,
some published case studies suggest that treatment of
MTrPs in shoulder patients may be beneficial [28-31].
The primary aim of this study is to investigate the effec-
tiveness of inactivation of MTrPs in shoulder muscles by
physical therapy on symptoms and functioning of the
shoulder in daily activities in a population of chronic a-
traumatic shoulder patients when compared to a wait-
and-see strategy. In addition, we investigate the recurrence
rate during a one-year-follow-up period.
Methods/Design
An examiner-blinded randomized controlled trial will be
conducted, which has been approved by the ethics com-
mittee of the Radboud University Nijmegen Medical Cen-
tre, the Netherlands [CMO 2007/022].
Participants/Study sample
Between September 2007 and September 2008, all con-
secutive patients referred to a physical therapy practice
specialized in the treatment of individuals with muscu-
loskeletal disorders of the neck, shoulder and arm are
potential study participants. The referring physicians
include general practioners, orthopaedic surgeons, neu-
rologists and physiatrists. Patients are eligible if they have
unilateral shoulder complaints (described as pain felt in
the shoulder or upper arm) for at least six months. The
patients present with persistent shoulder pain that has not
spontaneously recovered. The patients are between 18 and
65 years old. Because the questionnaires are in the DutchBMC Musculoskeletal Disorders 2007, 8:107 http://www.biomedcentral.com/1471-2474/8/107
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language, subjects must understand written and verbal
Dutch. Patients who have been diagnosed (prior to the
referral) with shoulder instability, shoulder fractures, sys-
temic diseases (such as rheumatoid arthritis, Reiter's syn-
drome, diabetes), or who's medical history or
examination suggests neurological diseases, or other
severe medical or psychiatric disorders will be excluded
from the study. The project leader will check all the avail-
able information from referral letters, additional informa-
tion from the general practitioner and from the patients.
All eligible patients will be informed of the study and will
be invited to participate. Patients who are willing to par-
ticipate will be asked to review and sign the written
informed consent.
Measurements
Before randomization, all participants will be assessed
during an individual baseline test session. They will com-
plete a battery of questionnaires and tests, determining
data on social, demographic, and physical factors, and
baseline values for the outcome measures. In addition,
subjects will complete the DASH, RAND-36-dutch lan-
guage version, and passive range of motion tests of the
shoulder (PROM). During the initial assessment, MTrPs
will be identified, based on compression-produced pain
that is recognized by patients as their own shoulder pain.
If no MTrPs are detected, the subjects will be excluded
from the study. All measurements will be performed by
the same independent observer, who is not employed by
the physical therapy practice (This is to create optimal
blinding of the observer, who is now not able to recognise
the subjects). The observer is trained in identifying MTrPs
and has several years of clinical experience in MTrP ther-
apy. The observer participated in a former reliability study
of MTrP palpation. The baseline measurements will be at
T0, the second measurement (T1) will be 6 weeks after the
first assessment session, the third (T2) will be 12 weeks
after the first assessment session. All measurements [see
box 1] will be performed outside the physical therapy
practice to assure that the observer will not recognise any
of the study participants when they come to the physical
therapy practice for their treatment. After this first assess-
ment, the patients will be randomly assigned to one of
two groups: the intervention group or the control group.
The patients in the control group will stay on the waiting
list and will not receive any treatment. They are allowed to
use over-the-counter painkillers during this 12-week
period. After 6 weeks and 12 weeks, respectively, they will
be examined by the same blinded observer. After 12 weeks
they will receive the same physical therapy program as the
experimental group [see Figure 1]. The initial trial ends
after 12 weeks, but 6 months and 12 months after the start
of the experimental intervention shoulder function of the
subjects will be re-evaluated with the DASH-Dutch lan-
guage version.
Intervention
The patients in the intervention group will be treated by a
physical therapist once a week for a maximum period of
12 weeks. All participating physiotherapists are experi-
enced in treating patients with long-lasting shoulder
symptoms and patients with MTrPs and myofascial pain,
especially in the upper part of the body. They are trained
and skilled in the identification of MTrPs and received a
certification in manual trigger point therapy. The treat-
ment starts with inactivation of the active (pain produc-
ing) MTrPs by using manual techniques (compression on
the trigger point, manual stretching of the trigger point
area and the taut band) combined with "intermittent cold
application by using ice-cubes followed by stretching the
muscle" according to Travell [32] to further inactivate the
MTrPs. Manual pressure will decrease the sensitivity of the
painful nodule in the muscle while other massage tech-
nique will mobilize and stretch the contracted muscle
fibres. The application of the ice-cubes has a desensitizing
effect, and makes it easier to stretch shoulder muscles.
Each treatment session will end with a heat application to
increase the circulation of the involved muscles.
Patients will be advised to do stretching exercises and will
be taught to perform these correctly by means of surface-
electromyography-assisted stretching[33,34]. Further-
more they will be advised to perform relaxation exercises,
and to applyheat (like a hot shower, hot packs) several
times (at least twice) a day. If there is abnormal measura-
ble higher electromyographic activity in the upper trape-
zius muscle (measured by surface Electromyography
(sEMG) using a Myomed 932 [Enraf Nonius, Delft, the
Netherlands]) during standing and/or sitting [35], relaxa-
tion exercises will be performed using a portable myo-
feedback device (Myotrac I, Thought Technology, Quebec,
Canada). Abnormal sEMG activity is defined as a con-
stantly measured value above 1%–5% of the maximally
voluntary contraction [36-39], which is in general above
10 microvolt, during several minutes and the patient is
not able to relax the muscle spontaneously or on request.
Finally, all patients will receive ergonomic recommenda-
tions, andinstructions to assume and maintain "good"
posture [40,41]. Manual high velocity thrust techniques
of the cervical spine and the shoulder and dry needling are
excluded from the treatment protocol, because not all par-
ticipating physical therapists are skilled to perform these
techniques. The content of each session may vary as it
depends on the findings during the first treatment session
and the results of the previous treatment sessions. Thus,
there are differences in the content of the individual treat-
ments, but within the limits of the treatment protocol.
Stoprule
The treatment ceases when the patient is completely
symptom-free or the patient and the therapist agree thatBMC Musculoskeletal Disorders 2007, 8:107 http://www.biomedcentral.com/1471-2474/8/107
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treatment will not further benefit the patient, although
their participation in the study will prolong. If patients
decide that they no longer wish to participate in the study
they are free to withdraw from the study at any moment.
Control of intervention integrity
To enhance the integrity of this complex intervention,
every week all participating physical therapists will discuss
the content of each therapy session with the researcher
(CB) without mentioning names or other information
which will assure the blinding of the independent
researcher (CB). After 6 and 12 weeks, the patients of the
intervention group will interviewed about the content of
the received treatment sessions to assure that all patients
will be treated according to the protocol. If patients are
not treated according to the protocol, they will be identi-
fied and participation may be discontinued.
Expectations regarding treatment outcome
At the start of the trial (T0) both the patients and physical
therapists will complete a questionnaire regarding the
anticipated treatment outcome.
Setting
The study will be conducted in a physical therapy practice
specialized in management of persons with musculoskel-
etal disorders of the neck, shoulder and arm. After ran-
domisation every patient assigned to the experimental
group will be treated by the same physical therapist.
Objectives
In the current study we will test the following hypothesis
(H0).
A physical therapy treatment to inactivate MTrPs within a
three months' period is as effective as a "wait and see"
approach of patients with chronic shoulder complaints in
a three month period.
recruitment and experimental plan Figure 1
recruitment and experimental plan.
orthopedic surgeon, neurologist
or Physiatrist
general practioner
presentation at physiotherapy
practice
refused n=
excluded n=
included, first assessment, checking health
status for exclusion criteria and randomisation
physiotherapy group n=
control group n=
wait and see for 12 weeks
drop outs and
withdrawals n=
drop outs and
withdrawals n=
assessment after 6 weeks
n= n=
final assessment after 12 weeks
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Population characteristics
• To identify potential confounding factors, demographic
information for all subjects will be collected including
age, gender, education, occupation, sports and leisure
activities, duration of the complaints, and type of onset,
among others.
• The Dutch language version of the RAND-36 item
Health Survey will be used for base line characteristics of
the study population. The RAND-36, which is almost
identical to the MOS SF-36 [42], scores the functional sta-
tus and quality of life and is widely used for screening
health status in medical, social and epidemiological
research. The RAND-36 consists of 36 items divided into
8 subscales concerning physical functioning, role limita-
tions due to physical health, role limitations due to emo-
tional problems, energy and fatigue, emotional well-
being, social functioning, pain, general health perception
and health change. This questionnaire is considered to be
a reliable instrument for comparing groups (internal con-
sistency Cronbach's alpha > 0.70). The test-retest stability
is sufficient (0.58 – 0.82) and the questionnaire is respon-
sive when scoring after at least 4 weeks. The construct
validity was estimated by comparing the RAND-36 with
other Health questionnaires (like the Nottingham Health
Profile [NHP] and the Groninger Activities Restriction
Scale [GARS]. There are significant correlations between
the subscales of the RAND-36 and the subscales of the
NHP (correlation coefficient 0.42 – 0.69). The correlation
coefficient between the subscale physical functioning and
the GARS is 0.65. A higher score (maximum is 100 points)
defines a more favourable health status.
• The Beck Depression Inventory (BDI) is used to discrim-
inate between patients with major depression and those
without or with minor depressive feelings. The BDI is
included because depression may be a confounding fac-
tor. The BDI is widely accepted and used in clinical and
experimental research and its predictive value is rated as
good. A BDI-score equally or higher than 21 indicates a
major depression (specificity 78.4%) [43].
Outcomes
The following outcome parameters will be used:
Primary
The overall score of the DASH (Disability of Arm Shoulder
and Hand) questionnaire – Dutch language version will
be used as the primary outcome measure. The DASH is a
multidimensional (physical, emotional and social) 30-
item self-report measure focussing on physical function
pain and other symptoms. At least 27 of the 30 items must
be completed for a score to be calculated. The assigned
values for all completed responses are simply summed
and averaged. This value is then transformed to a score out
of 100 by subtracting one and multiplying by 25. The
transformation is done to make the score easier to com-
pare to other measures using a 0–100 scale. A higher score
indicates greater disability.
where n is equal to the number of completed responses.
Scoring is on a 5-point Likert scale from no difficulty (0
points) to very difficult (5 points). The range of the total
score is from 0 to 100, where 0 means no symptoms
(pain, tingling, weakness or stiffness) and no difficulty in
performing daily activities, while 100 means extreme,
severe symptoms and unable to perform any daily activity.
Content and face validity of the DASH were confirmed by
a variety of experts of the American Academy of Orthopae-
dic Surgeons (AAOS), the council of Musculoskeletal Spe-
ciality Societies (COMSS) and the institute for Work and
Health (Toronto, Ontario, Canada) throughout the devel-
opment process [44].
Its internal consistency was excellent (Cronbach's alpha =
0.96) during field-testing. The test-retest reliability was
excellent (ICC2.1 = 0.92 and 0.96) in two studies [45,46]
and satisfactory in one study (Pearson 0.98 and kappa
0.67). The minimal detectable Change (MDC) was calcu-
lated in a population of 172 patients with several upper
limb disorders (Osteoarthritis, Carpal Tunnel syndrome,
Rotator Cuff syndrome, Rheumatoid Arthritis and Tennis
Elbow) [47]. The Minimal Detectable Change (MDC) var-
ied between 10.70 (at 90% confidence level) and 12.75
(at 95% confidence level). The DASH demonstrated to be
a responsive questionnaire.
The inter- and intra-observer reliability is good to excel-
lent (intra-observer reliability Pearson r = 0.96 to 0.98;
ICC = 0.91 to 0.96; Inter-observer agreement Cohen's
kappa = 0.79).
The construct validity was estimated by comparing the
DASH to several other questionnaires. The correlation
with other instruments like the SPADI (Shoulder Pain and
Disability Index) is good (Pearson's r = 0.82 to 0.88). The
DASH questionnaire is one of the best among 16 other
questionnaires for shoulder symptoms [48].
Secondary
An independent examiner will perform the following
tests.
• The total number of shoulder muscles with MTrPs will
be counted and compared to the baseline measurement
findings.
DASH disability/sympton score
sum of n responses
n
=
−
×
[( ) ] 1
25BMC Musculoskeletal Disorders 2007, 8:107 http://www.biomedcentral.com/1471-2474/8/107
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• Passive range of motion of the shoulder will be meas-
ured by an handheld digital inclinometer (The Saunders
group Inc, Chaska, MN). The range of motion of the non-
painful shoulder will be used as reference [49,49,50].
Because the normal range of motion differs from one indi-
vidual to another, we focus on improvement of limited
range of motion during the experiment (both experimen-
tal group and control group).
 For the measurement of passive external rotation, the
patient is in a supine position, with the shoulder in 0° of
abduction and rotation, the elbow flexed at 90° and the
forearm in a neutral position. This position is defined as
the position of 0°. The observer then performs external
rotation until pain limits the range of motion or the
extreme of the range is reached. The inclinometer is placed
against the volar side of the forearm. This range of motion
is recorded in degrees. The normal range of motion for
external rotation is between 70° and 90°.
 For the measurement of passive glenohumeral abduc-
tion, the patient is seated upright, and the position of 0°
is defined as the upper arm is in a neutral position. While
palpating the lower angle of the scapula with the thumb,
the examiner elevates the upper arm of the patient until
the scapula begins to rotate or pain limits further motion.
The inclinometer is placed against the lateral side of the
upper arm near the elbow. The range of motion is
recorded in degrees. The normal range of motion is 90°.
 For the measurement of passive elevation (through flex-
ion), the patient is in the supine position with the arm
along the side. This position is defined as the position of
0°. The observer than performs elevation until pain limits
the range of motion or the extreme of the range is reached.
Then the inclinometer is placed against the medial side of
the upper arm near the elbow. The range of motion is
recorded in degrees. The normal range of motion is
between 165° and 180°
 For the measurement of internal rotation the patient is
in a prone position. The shoulder is 90° abduction, and
the forearm is in neutral position. This position is defined
as the position of 0°. The observer than performs internal
rotation until pain limits the range of motion or the
extreme of the range is reached. The sensor is placed
against the volar side of the forearm. The normal range of
motion is 70°
 For the measurement of horizontal adduction the
patient is in a supine position. The arm is in 90° abduc-
tion. This position is defined as the position of 0°. The
observer performs adduction, while the arm stays in the
vertical plane, until pain limits the range of motion or the
extreme of the range is reached. The normal range of
motion is 135°
• Finally the total number of treatment sessions will be
counted. This is done by an assistant, who is not involved
in the study by using the administration-software of the
practice [see Table 1].
Sample size
The initial sample size is based on the assumption that the
overall score of the primary outcome measure DASH
shows a mean improvement of 15 points [SD = 22] [51].
Table 1: Overview of variables
Variable T0 Baseline T1 After 6 wk T2 After 12 wk Measured by
Age* X Interview
Gender* X Interview
Work X Interview
Dominant side affected X Interview
Duration of the complaints* X Interview
DASH DLV X X X Questionnaire
Use of medication X X X Interview
Use of other therapy X X X Interview
Work % X X X Interview
Improvement (percentage of perceived improvement) X X Interview
Number of involved muscles X X X Assessment
No. of treatment sessions X Assessment
Health status for baseline comparison X RAND-36 DLV
Existence and severity of symptoms of depression X Beck Depression Inventory
Shoulder Passive ROM XX X G o n i o m e t r y
• flexion X X X
• abduction X X X
• external rotation X X X
• internal rotation X X X
• cross body adduction X X X
*Age, gender and duration of the complaints seem to be important prognostic variables [53].BMC Musculoskeletal Disorders 2007, 8:107 http://www.biomedcentral.com/1471-2474/8/107
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To test the null hypothesis of equality of treatment at α =
.05 with 90% power and assuming a uniform dropout rate
of 5%, it was calculated that 52 patients in each group
would be sufficient.
Randomization
After inclusion the patients will be randomly assigned to
either the intervention group or the "wait and see" group.
The randomisation will be performed by an assistant not
otherwise involved in the study by generating random
numbers using computer software. Stratification or block-
ing strategies will not be used.
Informed consent
The patients will be informed about the study prior to the
first assessment and will be asked to give written informed
consent.
Blinding
Blinding of the patients or the physical therapists, who are
involved in the treatment, is impossible due to the treat-
ment characteristics.
An independent observer will collect baseline data and
outcome data. The independent observer is blinded. The
successfulness of the blinding procedure will be evaluated
by asking the observer to which group she believes the
subjects belong.
Statistical analysis
For comparisons of prognostic variables on baseline we
will use the Student's t test for continuous variables with
normal distribution and the chi-square test for categorical
variables or continuous variables with non-normal distri-
bution[52]. For the overall score of the DASH (primary
outcome measure) we will use the unpaired t-test for nor-
mally distributed data or Mann-Whitney Rank Sum-test
for non-normally distributed data to assess the difference
between the two groups after the treatments. Regression
analyses will be used to include prognostic factors, such as
the baseline scores like age, gender and duration of the
complaints, in the analyses. All significance levels will be
set at p < 0.05. All data will be analysed primarily accord-
ing to intention-to-treat principle. We will use Sigmastat
3.11 and Systat 12 for windows (Systat Inc. Richmond,
California, USA) for the statistical analyses.
Discussion
Since there is little evidence for the efficacy of physical
therapy interventions in some shoulder disorders, there is
a need for further research. Therefore we will perform a
randomised clinical trial dealing with the effect of physi-
cal therapy interventions aimed to inactivate MTrPs on
pain and impairment in shoulder function in a popula-
tion of chronic a-traumatic shoulder patients. To the best
of our knowledge, few studies of the efficacy of MTrP ther-
apy are published. We choose for an intervention strategy
that best reflects daily practice. We excluded manual high
velocity thrust techniques and intramuscular MTrP release
by dry needling, because these interventions are not com-
monly used by Dutch physical therapists and not all par-
ticipating therapists were skilled to perform these
techniques at the beginning of the study. In most physical
therapy interventions, blinding of the patient and the
therapist is not possible. The observers will be blinded for
the allocation procedure. The results of this trial will be
presented as soon as they are available.
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